Stock report · Delisted · Nasdaq

Soleno Therapeutics, Inc. (SLNO)

53.01USD Delisted Final close · May 15, 2026

SLNO no longer trades. Soleno Therapeutics was acquired by Neurocrine Biosciences for $53.00 per share in cash through a tender offer and merger completed on May 18, 2026.

All prices on this page are historical. The last trade was on May 15, 2026, at $53.01.

SLNO stock price history

Loading chart…
Split-adjusted closing prices, 2014–2026

Final trading statistics

Final close
$53.01
Final trading day
May 15, 2026
Market cap at delisting
$2.76B
Shares outstanding
52.12M
Final 52-week range
$29.43 – $90.32
Avg. volume (final 3 mo.)
3,411,767
All-time high
$656.25 · Mar 2015
All-time low
$0.89 · Dec 2022
Return since IPO
-81.8%
Beta
-2.22
Book value / share
$8.61
Price / book
6.16

About Soleno Therapeutics, Inc.

Soleno Therapeutics was a biopharmaceutical company based in Redwood City, California, focused on rare diseases. The company was founded in 1999 and was originally known as Capnia, Inc., a developer of products for neonatal and respiratory conditions that went public on Nasdaq in 2014. In 2017 it changed its name to Soleno Therapeutics and refocused on rare diseases, acquiring Essentialis, which held the rights to diazoxide choline.

Soleno's lead asset was Diazoxide Choline Extended-Release tablets, known as DCCR, a once-daily oral therapy developed for Prader-Willi syndrome, a rare genetic disorder marked by hyperphagia, an intense and persistent hunger, along with behavioral and metabolic complications. The company advanced the drug through a Phase 3 program, and results of its clinical studies supported a regulatory filing. Prader-Willi syndrome had no approved therapy for hyperphagia when the program began, which gave the candidate orphan-drug status and attention from patient advocacy groups.

The FDA approved the product, marketed as VYKAT XR (diazoxide choline) extended-release tablets, on March 26, 2025, for the treatment of hyperphagia in adults and children aged four and older with Prader-Willi syndrome. The approval transformed Soleno from a clinical-stage developer into a commercial-stage company, and it built out a launch organization to support prescribers and families. Its market value rose substantially following the approval.

On April 6, 2026, Soleno announced that it had agreed to be acquired by Neurocrine Biosciences, a San Diego-based neuroscience and endocrinology company listed on Nasdaq under NBIX. The transaction was valued at approximately $2.9 billion and was presented as a way for Neurocrine to expand into rare metabolic disease and add a newly launched commercial product to its portfolio.

The acquisition was structured as a two-step transaction. Neurocrine commenced a tender offer for all outstanding Soleno shares at $53.00 per share in cash, without interest and subject to withholding taxes. Soleno's board recommended that stockholders tender, and the company filed a Schedule 14D-9 with the SEC describing the board's recommendation and the background of the transaction. Shares not tendered were to be converted into the right to receive the same cash price in a follow-on merger.

The tender offer expired on May 15, 2026, and Neurocrine completed the acquisition through a merger announced on May 18, 2026. Soleno became a wholly owned subsidiary of Neurocrine, its common stock ceased trading on Nasdaq, and a Form 25 was filed to remove the shares from listing and registration. The company's rare disease franchise now operates as part of Neurocrine.

Exchange (former)
Nasdaq
Sector
Healthcare
Industry
Biotechnology
Headquarters
Redwood City, CA
Employees
182
IPO date
November 13, 2014
Delisted
May 15, 2026
SEC CIK
1484565

Soleno Therapeutics financials before the delisting

The last 5 fiscal years Soleno Therapeutics reported as a public company, fiscal year ending December.

SLNO revenue and net income

RevenueNet income

SLNO earnings per share

Earnings per share

SLNO annual financials

Soleno Therapeutics, Inc. revenue, net income and EPS by fiscal year
Fiscal yearRevenueNet incomeEPS
FY2025$190.41M$20.9M$0.23
FY2024$0.00−$175.8M−$4.26
FY2023$0.00−$39.0M−$2.97
FY2022$0.00−$24.1M−$3.32
FY2021$0.00−$30.9M−$5.85

Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.

Soleno Therapeutics stock FAQ

What happened to Soleno Therapeutics stock?

Soleno Therapeutics was acquired by Neurocrine Biosciences for $53.00 per share in cash through a tender offer and merger completed on May 18, 2026. The final close was $53.01 on May 15, 2026.

Can I still buy SLNO stock?

No. SLNO is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on May 15, 2026.

What was the last price of SLNO?

SLNO last closed at $53.01 on May 15, 2026, which valued the company at about $2.76B.

How did Soleno Therapeutics do in its last full fiscal year?

In fiscal 2025, its last full year as a public company, Soleno Therapeutics reported revenue of $190.41M and net income of $20.9M.

When did Soleno Therapeutics go public?

Soleno Therapeutics shares started trading on November 13, 2014.

SLNO no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.